RxDoctor Payments DataLook up a doctor →

Brian Poligone, MD

Dermatology · Fairport, NYNPI 1871798868

Payments from drug & device makers

$1,760,288in general payments, 2019–2025

Across 419 payments — averaging $4201.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Helsinn Therapeutics (U.S.), Inc.$663K
  • Otsuka Pharmaceutical Co., Ltd.$582K
  • Kyowa Kirin Pharmaceutical Development, Inc$132K
  • Stemline Therapeutics Inc.$94K
  • Mallinckrodt Enterprises LLC$67K
  • Helsinn Healthcare SA$54K
  • plus $168K from 24 others
$6,604in research payments, 2019–2025

Across 1 payment — averaging $6603.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$7K

What the payments were for

  • Consulting fees$70,58321%
  • Speaking & faculty fees$203,45859%
  • Grants$8920%
  • Travel & lodging$60,22918%
  • Food & beverage$7,7082%
  • Education$220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,760,288 in reported general payments places this provider in the 95th percentile of 1,151 dermatology providers in New York.

See all dermatology providers in New York

Medicare billing

Part B allowed, 2024
$21,533
Medicare patients
49
Services billed
238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Bexarotene47$1,275,343
ValchlorMechlorethamine Hcl52$394,951
PegasysPeginterferon Alfa-2a12$97,981
Dupixent SyringeDupilumab15$55,696
Levothyroxine Sodium29$2,013
Betamethasone Dipropionate60$1,497
Clobetasol Propionate29$1,110
MethotrexateMethotrexate Sodium35$802
Imiquimod27$771
Triamcinolone Acetonide19$207
Atorvastatin Calcium15$85

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Helsinn Healthcare SAValchlor$54,105$394,95152 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,151 dermatology providers in New York.

Other dermatology in Fairport

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →